{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:55:29Z","timestamp":1788519329093,"version":"build-2803163510"},"reference-count":247,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303831"],"award-info":[{"award-number":["82303831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273323"],"award-info":[{"award-number":["82273323"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Radiotherapy is widely used in cancer treatment in both curative and palliative care due to its good safety profile and broad clinical availability. It not only directly destroys tumor cells by damaging their DNA but also plays a critical immunomodulatory role, making it a potential combination partner for immunotherapy. Radiotherapy-induced immune effects are complex. They could enhance antitumor immunity by releasing tumor antigens but also promote tumor immune evasion by adaptively regulating immunosuppressive molecules, such as phagocytosis checkpoints. However, the effects of radiotherapy on phagocytosis checkpoints are not fully elaborated compared to T cell-associated immune checkpoints. Phagocytosis checkpoints are regulated by a series of receptor-ligand binding molecules, respectively on the tumor cells and phagocytes, which mediate pro-phagocytosis or anti-phagocytosis signals, modulate tumor antigen presentation, and further determine the infiltration of tumor-specific cytotoxic T cells in the tumor microenvironment. Radiotherapy regulates the different phagocytosis checkpoints on the tumor cells and phagocytes to modulate phagocytic clearance and reshape the irradiated tumor microenvironment. Therefore, radiotherapy in combination with phagocytosis checkpoints-associated immunotherapy can be a promising antitumor approach by considering the type, dose, and sequence of this combinatory regimen as well as the biomarkers for patient selection. This review attempts to summarize the cross-effects of radiotherapy and phagocytosis checkpoints and their combination strategies to enhance the efficiency of radiotherapy and improve the survival of cancer patients. Opportunities built on the roles of the phagocytosis checkpoint in radiotherapy are duly warranted.<\/jats:p>","DOI":"10.1038\/s41419-025-07921-5","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T03:28:13Z","timestamp":1755660493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Roles of the phagocytosis checkpoint in radiotherapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Yulan","family":"Kui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-8316","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"7921_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMra1608986","volume":"377","author":"DE Citrin","year":"2017","unstructured":"Citrin DE. Recent Developments in Radiotherapy. N Engl J Med. 2017;377:1065\u201375.","journal-title":"N Engl J Med"},{"key":"7921_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5:60.","journal-title":"Signal Transduct Target Ther"},{"key":"7921_CR3","doi-asserted-by":"crossref","unstructured":"Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259\u201371.","DOI":"10.1084\/jem.20052494"},{"key":"7921_CR4","doi-asserted-by":"publisher","first-page":"e138740.","DOI":"10.1172\/JCI138740","volume":"131","author":"C Lhuillier","year":"2021","unstructured":"Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L. et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Investig. 2021;131:e138740.","journal-title":"J Clin Investig"},{"key":"7921_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1523097","volume":"8","author":"J Krombach","year":"2019","unstructured":"Krombach J, Hennel R, Brix N, Orth M, Schoetz U, Ernst A, et al. Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology. 2019;8:e1523097.","journal-title":"Oncoimmunology"},{"key":"7921_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.18632\/oncotarget.1719","volume":"5","author":"SR Gameiro","year":"2014","unstructured":"Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403\u201316.","journal-title":"Oncotarget"},{"key":"7921_CR7","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/sj.cdd.4402201","volume":"14","author":"M Obeid","year":"2007","unstructured":"Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14:1848\u201350.","journal-title":"Cell Death Differ"},{"key":"7921_CR8","doi-asserted-by":"publisher","first-page":"16003","DOI":"10.1002\/jcp.28258","volume":"234","author":"SY Wu","year":"2019","unstructured":"Wu SY, Chen CL, Tseng PC, Chiu CY, Lin YE, Lin CF. Fractionated ionizing radiation facilitates interferon-\u03b3 signaling and anticancer activity in lung adenocarcinoma cells. J Cell Physiol. 2019;234:16003\u201310.","journal-title":"J Cell Physiol"},{"key":"7921_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1470-2045(02)00900-2","volume":"3","author":"RR Weichselbaum","year":"2002","unstructured":"Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, et al. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002;3:665\u201371.","journal-title":"Lancet Oncol"},{"key":"7921_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/imr.12573","volume":"280","author":"N Brix","year":"2017","unstructured":"Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249\u201379.","journal-title":"Immunol Rev"},{"key":"7921_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2019.00317","volume":"10","author":"J Liu","year":"2019","unstructured":"Liu J, Zhou J, Wu M, Hu C, Yang J, Li D, et al. Low-dose total body irradiation can enhance systemic immune related response induced by hypo-fractionated radiation. Front Immunol. 2019;10:317.","journal-title":"Front Immunol"},{"key":"7921_CR12","doi-asserted-by":"publisher","first-page":"103226","DOI":"10.1016\/j.critrevonc.2021.103226","volume":"159","author":"MI Koukourakis","year":"2021","unstructured":"Koukourakis MI, Giatromanolaki A. Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy. Crit Rev Oncol\/Hematol. 2021;159:103226.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"7921_CR13","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","volume":"75","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, et al. TGF\u03b2 is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75:2232\u201342.","journal-title":"Cancer Res"},{"key":"7921_CR14","doi-asserted-by":"publisher","first-page":"e9342.","DOI":"10.15252\/emmm.201809342","volume":"10","author":"KI Jones","year":"2018","unstructured":"Jones KI, Tiersma J, Yuzhalin AE, Gordon-Weeks AN, Buzzelli J, Im JH. et al. Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol Med. 2018;10:e9342.","journal-title":"EMBO Mol Med"},{"key":"7921_CR15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","volume":"5","author":"Y Muroyama","year":"2017","unstructured":"Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, et al. Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment. Cancer Immunol Res. 2017;5:992\u20131004.","journal-title":"Cancer Immunol Res"},{"key":"7921_CR16","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2326-6066.CIR-20-0111","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, Lu Y, Hang J, Zhang J, Zhang T, Huo Y, et al. Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol Res. 2020;8:1440\u201351.","journal-title":"Cancer Immunol Res"},{"key":"7921_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","volume":"8","author":"KB Pointer","year":"2022","unstructured":"Pointer KB, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy: open questions and future strategies. Trends cancer. 2022;8:9\u201320.","journal-title":"Trends cancer"},{"key":"7921_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol cancer. 2022;21:28.","journal-title":"Mol cancer"},{"key":"7921_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58\u201367.","journal-title":"Blood"},{"key":"7921_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19:568\u201386.","journal-title":"Nat Rev Cancer"},{"key":"7921_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8:104.","journal-title":"Signal Transduct Target Ther"},{"key":"7921_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189172","volume":"1879","author":"Z Li","year":"2024","unstructured":"Li Z, Han B, Qi M, Li Y, Duan Y, Yao Y. Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy. Biochim Biophys Acta Rev cancer. 2024;1879:189172.","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"7921_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41577-023-00921-6","volume":"24","author":"GC Brown","year":"2024","unstructured":"Brown GC. Cell death by phagocytosis. Nat Rev Immunol. 2024;24:91\u2013102.","journal-title":"Nat Rev Immunol"},{"key":"7921_CR24","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.7150\/ijbs.60782","volume":"17","author":"X Jia","year":"2021","unstructured":"Jia X, Yan B, Tian X, Liu Q, Jin J, Shi J, et al. CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy. Int J Biol Sci. 2021;17:3281\u20137.","journal-title":"Int J Biol Sci"},{"key":"7921_CR25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma. N Engl J Med. 2018;379:1711\u201321.","journal-title":"N Engl J Med"},{"key":"7921_CR26","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-Human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol: J Am Soc Clin Oncol. 2019;37:946\u201353.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"7921_CR27","doi-asserted-by":"publisher","first-page":"e1373235","DOI":"10.1080\/2162402X.2017.1373235","volume":"7","author":"CM Sch\u00fcrch","year":"2017","unstructured":"Sch\u00fcrch CM, Forster S, Br\u00fchl F, Yang SH, Felley-Bosco E, Hewer E. The \u201cdon\u2019t eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma. Oncoimmunology. 2017;7:e1373235.","journal-title":"Oncoimmunology"},{"key":"7921_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23:295\u2013316.","journal-title":"Nat Rev Cancer"},{"key":"7921_CR29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2:1124\u201335.","journal-title":"Nat Cancer"},{"key":"7921_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1827","volume":"10","author":"J Wang","year":"2024","unstructured":"Wang J, Gai J, Zhang T, Niu N, Qi H, Thomas DL, et al. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Sci Adv. 2024;10:eadk1827.","journal-title":"Sci Adv"},{"key":"7921_CR31","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","volume":"15","author":"A Abravan","year":"2020","unstructured":"Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, van Herk M. Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer. J Thorac Oncol: Publ Int Assoc Study Lung Cancer. 2020;15:1624\u201335.","journal-title":"J Thorac Oncol: Publ Int Assoc Study Lung Cancer"},{"key":"7921_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijrobp.2021.04.009","volume":"111","author":"E Reijmen","year":"2021","unstructured":"Reijmen E, De Mey S, De Mey W, Gevaert T, De Ridder K, Locy H, et al. Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors. Int J Radiat Oncol, Biol, Phys. 2021;111:272\u201383.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"7921_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","volume":"23","author":"JD Schoenfeld","year":"2022","unstructured":"Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022;23:279\u201391.","journal-title":"Lancet Oncol"},{"key":"7921_CR34","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1158\/0008-5472.CAN-17-3623","volume":"78","author":"M Rafat","year":"2018","unstructured":"Rafat M, Aguilera TA, Vilalta M, Bronsart LL, Soto LA, von Eyben R, et al. Macrophages promote circulating tumor cell-mediated local recurrence following radiotherapy in immunosuppressed patients. Cancer Res. 2018;78:4241\u201352.","journal-title":"Cancer Res"},{"key":"7921_CR35","doi-asserted-by":"crossref","unstructured":"Stary V, Wolf B, Unterleuthner D, List J, Talic M, Laengle J, et al. Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer. J Immunother Cancer. 2020;8(2):e000667.","DOI":"10.1136\/jitc-2020-000667"},{"key":"7921_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101887","volume":"6","author":"H Wang","year":"2025","unstructured":"Wang H, Zhai M, Li M, Han C, Liu L, Huang C, et al. Phenotypic plasticity and increased infiltration of peripheral blood-derived TREM1(+) mono-macrophages following radiotherapy in rectal cancer. Cell Rep Med. 2025;6:101887.","journal-title":"Cell Rep Med"},{"key":"7921_CR37","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/0008-5472.CAN-14-0037-T","volume":"74","author":"DR Soto-Pantoja","year":"2014","unstructured":"Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, et al. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 2014;74:6771\u201383.","journal-title":"Cancer Res"},{"key":"7921_CR38","doi-asserted-by":"crossref","unstructured":"Wang H, Sun Y, Zhou X, Chen C, Jiao L, Li W, et al. CD47\/SIRP\u03b1 blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. J Immunothe Cancer. 2020;8:e000905.","DOI":"10.1136\/jitc-2020-000905"},{"key":"7921_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101159","volume":"8","author":"K Okada","year":"2023","unstructured":"Okada K, Sato H, Kumazawa T, Mori Y, Permata TBM, Uchihara Y, et al. Calreticulin upregulation in cervical cancer tissues from patients after 10 Gy radiation therapy. Adv Radiat Oncol. 2023;8:101159.","journal-title":"Adv Radiat Oncol"},{"key":"7921_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature"},{"key":"7921_CR41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76\u201384.","journal-title":"Nat Immunol"},{"key":"7921_CR42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392\u20136.","journal-title":"Nature"},{"key":"7921_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41586-019-1088-4","volume":"568","author":"JV Pluvinage","year":"2019","unstructured":"Pluvinage JV, Haney MS, Smith BAH, Sun J, Iram T, Bonanno L, et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature. 2019;568:187\u201392.","journal-title":"Nature"},{"key":"7921_CR44","first-page":"eabj5501","volume":"7","author":"D Li","year":"2022","unstructured":"Li D, Xiong W, Wang Y, Feng J, He Y, Du J, et al. SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors. Sci Immunol. 2022;7:eabj5501.","journal-title":"Sci Immunol"},{"key":"7921_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","volume":"28","author":"J Theruvath","year":"2022","unstructured":"Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022;28:333\u201344.","journal-title":"Nat Med"},{"key":"7921_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","volume":"32","author":"AN Barclay","year":"2014","unstructured":"Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25\u201350.","journal-title":"Annu Rev Immunol"},{"key":"7921_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","volume":"10","author":"X Liu","year":"2017","unstructured":"Liu X, Kwon H, Li Z, Fu YX. Is CD47 an innate immune checkpoint for tumor evasion?. J Hematol Oncol. 2017;10:12.","journal-title":"J Hematol Oncol"},{"key":"7921_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276:145\u201364.","journal-title":"Immunol Rev"},{"key":"7921_CR49","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRP\u03b1 Immune Checkpoint. Immunity. 2020;52:742\u201352.","journal-title":"Immunity"},{"key":"7921_CR50","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Investig. 2016;126:2610\u201320.","journal-title":"J Clin Investig"},{"key":"7921_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Sci (NY). 2016;352:227\u201331.","journal-title":"Sci (NY)"},{"key":"7921_CR52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.27859","volume":"62","author":"J Lo","year":"2015","unstructured":"Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatol (Balt, Md). 2015;62:534\u201345.","journal-title":"Hepatol (Balt, Md)"},{"key":"7921_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216205","volume":"564","author":"J Lu","year":"2023","unstructured":"Lu J, Li J, Lin Z, Li H, Lou L, Ding W, et al. Reprogramming of TAMs via the STAT3\/CD47-SIRP\u03b1 axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Lett. 2023;564:216205.","journal-title":"Cancer Lett"},{"key":"7921_CR54","doi-asserted-by":"publisher","first-page":"E6215","DOI":"10.1073\/pnas.1520032112","volume":"112","author":"H Zhang","year":"2015","unstructured":"Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci USA. 2015;112:E6215\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7921_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119150","volume":"273","author":"Z Li","year":"2021","unstructured":"Li Z, Li Y, Gao J, Fu Y, Hua P, Jing Y, et al. The role of CD47-SIRP\u03b1 immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sci. 2021;273:119150.","journal-title":"Life Sci"},{"key":"7921_CR56","doi-asserted-by":"crossref","unstructured":"van Duijn A, Van der Burg SH, Scheeren FA. CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity. J Immunother Cancer. 2022;10:e004589.","DOI":"10.1136\/jitc-2022-004589"},{"key":"7921_CR57","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3892\/etm.2022.11478","volume":"24","author":"WH Lee","year":"2022","unstructured":"Lee WH, Kim SH, An JH, Kim TK, Cha HJ, Chang HW, et al. Tristetraprolin regulates phagocytosis through interaction with CD47 in head and neck cancer. Exp Ther Med. 2022;24:541.","journal-title":"Exp Ther Med"},{"key":"7921_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun. 2022;13:1511.","journal-title":"Nat Commun"},{"key":"7921_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18245-7","volume":"11","author":"D Candas-Green","year":"2020","unstructured":"Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, et al. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020;11:4591.","journal-title":"Nat Commun"},{"key":"7921_CR60","doi-asserted-by":"publisher","first-page":"eabl9330","DOI":"10.1126\/sciimmunol.abl9330","volume":"7","author":"RC Hsieh","year":"2022","unstructured":"Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol. 2022;7:eabl9330.","journal-title":"Sci Immunol"},{"key":"7921_CR61","doi-asserted-by":"publisher","first-page":"e0273547","DOI":"10.1371\/journal.pone.0273547","volume":"17","author":"E Rostami","year":"2022","unstructured":"Rostami E, Bakhshandeh M, Ghaffari-Nazari H, Alinezhad M, Alimohammadi M, Alimohammadi R, et al. Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments. PloS One. 2022;17:e0273547.","journal-title":"PloS One"},{"key":"7921_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01472-4","volume":"9","author":"K Ji","year":"2023","unstructured":"Ji K, Zhang Y, Jiang S, Sun L, Zhang B, Hu D, et al. SIRP\u03b1 blockade improves the antitumor immunity of radiotherapy in colorectal cancer. Cell Death Discov. 2023;9:180.","journal-title":"Cell Death Discov"},{"key":"7921_CR63","doi-asserted-by":"crossref","unstructured":"Piffk\u00f3 A, Yang K, Panda A, Heide J, Tesak K, Wen C, et al. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025;643:810\u201319.","DOI":"10.1038\/s41586-025-08994-0"},{"key":"7921_CR64","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ijc.28015","volume":"133","author":"DW Vermeer","year":"2013","unstructured":"Vermeer DW, Spanos WC, Vermeer PD, Bruns AM, Lee KM, Lee JH. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer. 2013;133:120\u20139.","journal-title":"Int J Cancer"},{"key":"7921_CR65","first-page":"4204","volume":"12","author":"L Shi","year":"2019","unstructured":"Shi L, Wang X, Hu B, Wang D, Ren Z. miR-222 enhances radiosensitivity of cancer cells by inhibiting the expression of CD47. Int J Clin Exp Pathol. 2019;12:4204\u201313.","journal-title":"Int J Clin Exp Pathol"},{"key":"7921_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216605","volume":"583","author":"T Sun","year":"2024","unstructured":"Sun T, Liu B, Cao Y, Li Y, Cai L, Yang W. AMPK-mediated CD47 H3K4 methylation promotes phagocytosis evasion of glioma stem cells post-radiotherapy. Cancer Lett. 2024;583:216605.","journal-title":"Cancer Lett"},{"key":"7921_CR67","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","volume":"3","author":"Y Nishiga","year":"2022","unstructured":"Nishiga Y, Drainas AP, Baron M, Bhattacharya D, Barkal AA, Ahrari Y, et al. Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nat Cancer. 2022;3:1351\u201366.","journal-title":"Nat Cancer"},{"key":"7921_CR68","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.trecan.2022.12.005","volume":"9","author":"E Guilbaud","year":"2023","unstructured":"Guilbaud E, Yamazaki T, Galluzzi L. T cell-independent abscopal responses to radiotherapy. Trends Cancer. 2023;9:93\u20135.","journal-title":"Trends Cancer"},{"key":"7921_CR69","doi-asserted-by":"crossref","unstructured":"Buchwald ZS, Nasti TH, Lee J, Eberhardt CS, Wieland A, Im SJ, et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J Immunother Cancer. 2020;8:e000867.","DOI":"10.1136\/jitc-2020-000867"},{"key":"7921_CR70","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39:644\u201355.","journal-title":"Trends Immunol"},{"key":"7921_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Gadwa J, Pham TT, Van Court B, Neupert B, Olimpo NA, et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun. 2022;13:7015.","journal-title":"Nat Commun"},{"key":"7921_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic I, Yong CSM, Kurz L, Vetrugno I, Reichl S, Fernandez AS, et al. Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat Commun. 2024;15:5500.","journal-title":"Nat Commun"},{"key":"7921_CR73","doi-asserted-by":"publisher","first-page":"1658.","DOI":"10.3390\/cells8121658","volume":"8","author":"S Pai","year":"2019","unstructured":"Pai S, Bamodu OA, Lin YK, Lin CS, Chu PY, Chien MH, et al. CD47-SIRP\u00e0 signaling induces epithelial-mesenchymal transition and cancer stemness and links to a poor prognosis in patients with oral squamous cell carcinoma. Cells. 2019;8:1658.","journal-title":"Cells"},{"key":"7921_CR74","doi-asserted-by":"crossref","unstructured":"Pai S, Yadav VK, Kuo KT, Pikatan NW, Lin CS, Chien MH, et al. PDK1 Inhibitor BX795 improves Cisplatin and radio-efficacy in oral squamous cell carcinoma by downregulating the PDK1\/CD47\/Akt-mediated glycolysis signaling pathway. Int J Mol Sci. 2021;22:11492.","DOI":"10.3390\/ijms222111492"},{"key":"7921_CR75","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1517\/14728222.2013.733699","volume":"17","author":"DR Soto-Pantoja","year":"2013","unstructured":"Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD. Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther targets. 2013;17:89\u2013103.","journal-title":"Expert Opin Ther targets"},{"key":"7921_CR76","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijrobp.2016.03.007","volume":"96","author":"M Boerma","year":"2016","unstructured":"Boerma M, Freeman ML. Radiation biology: targeting CD47 in cancer growth inhibition and normal tissue protection. Int J Radiat Oncol, Biol, Phys. 2016;96:245\u20137.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"7921_CR77","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2353\/ajpath.2008.080237","volume":"173","author":"JS Isenberg","year":"2008","unstructured":"Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG, et al. Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol. 2008;173:1100\u201312.","journal-title":"Am J Pathol"},{"key":"7921_CR78","doi-asserted-by":"publisher","first-page":"3ra7","DOI":"10.1126\/scitranslmed.3000139","volume":"1","author":"JB Maxhimer","year":"2009","unstructured":"Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, Tsokos M, et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med. 2009;1:3ra7.","journal-title":"Sci Transl Med"},{"key":"7921_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/srep01038","volume":"3","author":"DR Soto-Pantoja","year":"2013","unstructured":"Soto-Pantoja DR, Ridnour LA, Wink DA, Roberts DD. Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep. 2013;3:1038.","journal-title":"Sci Rep"},{"key":"7921_CR80","doi-asserted-by":"crossref","unstructured":"Soto-Pantoja DR, Isenberg JS, Roberts DD. Therapeutic targeting of CD47 to modulate tissue responses to ischemia and radiation. J Genet Syndromes Gene Ther. 2011;2:1000105.","DOI":"10.4172\/2157-7412.1000105"},{"key":"7921_CR81","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"7921_CR82","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767\u201378.","journal-title":"N Engl J Med"},{"key":"7921_CR83","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"7921_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03342-6","volume":"20","author":"H Yang","year":"2022","unstructured":"Yang H, Yan M, Li W, Xu L. SIRP\u03b1 and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma. J Transl Med. 2022;20:140.","journal-title":"J Transl Med"},{"key":"7921_CR85","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/carcin\/bgz177","volume":"41","author":"D Schulz","year":"2020","unstructured":"Schulz D, Streller M, Piendl G, Brockhoff G, Reichert TE, Menevse AN, et al. Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma. Carcinogenesis. 2020;41:984\u201392.","journal-title":"Carcinogenesis"},{"key":"7921_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.595466","volume":"10","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhou F, Wang Y, Xie H, Luo S, Meng L, et al. Eliminating radiation resistance of non-small cell lung cancer by Dihydroartemisinin through abrogating immunity escaping and promoting radiation sensitivity by inhibiting PD-L1 Expression. Front Oncol. 2020;10:595466.","journal-title":"Front Oncol"},{"key":"7921_CR87","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1158\/2326-6066.CIR-19-0744","volume":"8","author":"D Chen","year":"2020","unstructured":"Chen D, Barsoumian HB, Yang L, Younes AI, Verma V, Hu Y, et al. SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an Anti-PD-1-resistant model of non-small cell lung cancer. Cancer Immunol Res. 2020;8:883\u201394.","journal-title":"Cancer Immunol Res"},{"key":"7921_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751.","journal-title":"Nat Commun"},{"key":"7921_CR89","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","volume":"112","author":"SS Du","year":"2022","unstructured":"Du SS, Chen GW, Yang P, Chen YX, Hu Y, Zhao QQ, et al. Radiation Therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol, Biol, Phys. 2022;112:1243\u201355.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"7921_CR90","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74:5458\u201368.","journal-title":"Cancer Res"},{"key":"7921_CR91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2018.01.027","volume":"28","author":"X Song","year":"2018","unstructured":"Song X, Shao Y, Jiang T, Ding Y, Xu B, Zheng X, et al. Radiotherapy upregulates programmed death ligand-1 through the pathways downstream of epidermal growth factor receptor in glioma. EBioMedicine. 2018;28:105\u201313.","journal-title":"EBioMedicine"},{"key":"7921_CR92","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124:687\u201395.","journal-title":"J Clin Investig"},{"key":"7921_CR93","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","volume":"23","author":"SJ Dovedi","year":"2017","unstructured":"Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res : J Am Assoc Cancer Res. 2017;23:5514\u201326.","journal-title":"Clin Cancer Res : J Am Assoc Cancer Res"},{"key":"7921_CR94","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11:823\u201336.","journal-title":"Nat Rev Immunol"},{"key":"7921_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1240275","volume":"14","author":"T Zeller","year":"2023","unstructured":"Zeller T, M\u00fcnnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, et al. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Front Immunol. 2023;14:1240275.","journal-title":"Front Immunol"},{"key":"7921_CR96","doi-asserted-by":"crossref","unstructured":"Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, et al. BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression. J Immunother Cancer. 2022;10:e004859.","DOI":"10.1136\/jitc-2022-004859"},{"key":"7921_CR97","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3171\/jns.1994.80.6.1074","volume":"80","author":"B Klein","year":"1994","unstructured":"Klein B, Loven D, Lurie H, Rakowsky E, Nyska A, Levin I, et al. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J Neurosurg. 1994;80:1074\u20137.","journal-title":"J Neurosurg"},{"key":"7921_CR98","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21873\/cgp.20311","volume":"19","author":"T Hrbac","year":"2022","unstructured":"Hrbac T, Kopkova A, Siegl F, Vecera M, Ruckova M, Kazda T, et al. HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation. Cancer Genomics Proteom. 2022;19:151\u201362.","journal-title":"Cancer Genomics Proteom"},{"key":"7921_CR99","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0360-3016(97)00372-6","volume":"39","author":"AD Santin","year":"1997","unstructured":"Santin AD, Hermonat PL, Hiserodt JC, Chiriva-Internati M, Woodliff J, Theus JW, et al. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J Radiat Oncol, Biol, Phys. 1997;39:737\u201342.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"7921_CR100","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","volume":"64","author":"CT Garnett","year":"2004","unstructured":"Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985\u201394.","journal-title":"Cancer Res"},{"key":"7921_CR101","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1006\/gyno.1996.0075","volume":"60","author":"AD Santin","year":"1996","unstructured":"Santin AD, Hiserodt JC, Fruehauf J, DiSaia PJ, Pecorelli S, Granger GA. Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gynecol Oncol. 1996;60:468\u201374.","journal-title":"Gynecol Oncol"},{"key":"7921_CR102","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3892\/ijo.2017.3916","volume":"50","author":"L Haeggblom","year":"2017","unstructured":"Haeggblom L, Nordfors C, Tertipis N, Bersani C, Ramqvist T, N\u00e4sman A, et al. Effects of irradiation on human leukocyte antigen class I expression in human papillomavirus positive and negative base of tongue and mobile tongue squamous cell carcinoma cell lines. Int J Oncol. 2017;50:1423\u201330.","journal-title":"Int J Oncol"},{"key":"7921_CR103","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12964-023-01315-w","volume":"21","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhu G, Yang L, Yang Y. Targeting CD24 as a novel immunotherapy for solid cancers. Cell Commun Signal: CCS. 2023;21:312.","journal-title":"Cell Commun Signal: CCS"},{"key":"7921_CR104","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri2056","volume":"7","author":"PR Crocker","year":"2007","unstructured":"Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255\u201366.","journal-title":"Nat Rev Immunol"},{"key":"7921_CR105","doi-asserted-by":"publisher","first-page":"e0139112","DOI":"10.1371\/journal.pone.0139112","volume":"10","author":"MJ Kwon","year":"2015","unstructured":"Kwon MJ, Han J, Seo JH, Song K, Jeong HM, Choi JS, et al. CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. PloS One. 2015;10:e0139112.","journal-title":"PloS One"},{"key":"7921_CR106","doi-asserted-by":"crossref","unstructured":"Shen W, Shi P, Dong Q, Zhou X, Chen C, Sui X, et al. Discovery of a novel dual-targeting D-peptide to block CD24\/Siglec-10 and PD-1\/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. J Immunother Cancer. 2023;11:e007068.","DOI":"10.1136\/jitc-2023-007068"},{"key":"7921_CR107","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mc.22273","volume":"55","author":"J Bensimon","year":"2016","unstructured":"Bensimon J, Biard D, Paget V, Goislard M, Morel-Altmeyer S, Konge J, et al. Forced extinction of CD24 stem-like breast cancer marker alone promotes radiation resistance through the control of oxidative stress. Mol Carcinogenesis. 2016;55:245\u201354.","journal-title":"Mol Carcinogenesis"},{"key":"7921_CR108","doi-asserted-by":"publisher","first-page":"12402","DOI":"10.1073\/pnas.1304888110","volume":"110","author":"J M\u00fcller","year":"2013","unstructured":"M\u00fcller J, Obermeier I, W\u00f6hner M, Brandl C, Mrotzek S, Angerm\u00fcller S, et al. CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc Natl Acad Sci USA. 2013;110:12402\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7921_CR109","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","volume":"20","author":"S Bournazos","year":"2020","unstructured":"Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20:633\u201343.","journal-title":"Nat Rev Immunol"},{"key":"7921_CR110","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1182\/blood.V86.12.4389.bloodjournal86124389","volume":"86","author":"ZK Indik","year":"1995","unstructured":"Indik ZK, Park JG, Hunter S, Schreiber AD. The molecular dissection of Fc gamma receptor mediated phagocytosis. Blood. 1995;86:4389\u201399.","journal-title":"Blood"},{"key":"7921_CR111","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","volume":"124","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, et al. Inhibition of Fc\u03b3R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc\u03b3RIIb in human macrophages. Blood. 2014;124:3709\u201318.","journal-title":"Blood"},{"key":"7921_CR112","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1189\/jlb.0902454","volume":"73","author":"ZY Huang","year":"2003","unstructured":"Huang ZY, Hunter S, Kim MK, Indik ZK, Schreiber AD. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA. J Leukoc Biol. 2003;73:823\u20139.","journal-title":"J Leukoc Biol"},{"key":"7921_CR113","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/j.seminoncol.2014.07.003","volume":"41","author":"K Dobrenkov","year":"2014","unstructured":"Dobrenkov K, Cheung NK. GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol. 2014;41:589\u2013612.","journal-title":"Semin Oncol"},{"key":"7921_CR114","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","volume":"31","author":"J Fucikova","year":"2021","unstructured":"Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021;31:5\u201316.","journal-title":"Cell Res"},{"key":"7921_CR115","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"7921_CR116","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","volume":"123","author":"SJ Gardai","year":"2005","unstructured":"Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321\u201334.","journal-title":"Cell"},{"key":"7921_CR117","doi-asserted-by":"publisher","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","volume":"2","author":"MP Chao","year":"2010","unstructured":"Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2:63ra94.","journal-title":"Sci Transl Med"},{"key":"7921_CR118","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2020.12.023","volume":"39","author":"H Lin","year":"2021","unstructured":"Lin H, Kryczek I, Li S, Green MD, Ali A, Hamasha R, et al. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer cell. 2021;39:480\u201393.e6.","journal-title":"Cancer cell"},{"key":"7921_CR119","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.apsb.2021.06.002","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Luo X, Zhou Q, Gong H, Gao H, Liu T, et al. The disbalance of LRP1 and SIRP\u03b1 by psychological stress dampens the clearance of tumor cells by macrophages. Acta Pharm Sin B. 2022;12:197\u2013209.","journal-title":"Acta Pharm Sin B"},{"key":"7921_CR120","doi-asserted-by":"publisher","first-page":"86937","DOI":"10.18632\/oncotarget.13520","volume":"7","author":"AS Malamas","year":"2016","unstructured":"Malamas AS, Gameiro SR, Knudson KM, Hodge JW. Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas\u2019 sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget. 2016;7:86937\u201347.","journal-title":"Oncotarget"},{"key":"7921_CR121","doi-asserted-by":"publisher","first-page":"542","DOI":"10.21037\/atm.2019.09.128","volume":"7","author":"Y Huang","year":"2019","unstructured":"Huang Y, Dong Y, Zhao J, Zhang L, Kong L, Lu JJ. Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines. Ann Transl Med. 2019;7:542.","journal-title":"Ann Transl Med"},{"key":"7921_CR122","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3389\/fonc.2020.01610","volume":"10","author":"Y Huang","year":"2020","unstructured":"Huang Y, Huang Q, Zhao J, Dong Y, Zhang L, Fang X, et al. The impacts of different types of radiation on the CRT and PDL1 Expression in tumor cells under Normoxia and Hypoxia. Front Oncol. 2020;10:1610.","journal-title":"Front Oncol"},{"key":"7921_CR123","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40164-022-00371-1","volume":"12","author":"Z Gong","year":"2023","unstructured":"Gong Z, Jia Q, Guo J, Li C, Xu S, Jin Z, et al. Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism. Exp Hematol Oncol. 2023;12:7.","journal-title":"Exp Hematol Oncol"},{"key":"7921_CR124","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8753309","volume":"2023","author":"CJ Chen","year":"2023","unstructured":"Chen CJ, Hu YC, Chien Y, Huang WC, Wu CS, Tsai CY, et al. Calreticulin Expression controls cellular redox, stemness, and radiosensitivity to function as a novel adjuvant for radiotherapy in neuroblastoma. Oxid Med Cell Longev. 2023;2023:8753309.","journal-title":"Oxid Med Cell Longev"},{"key":"7921_CR125","doi-asserted-by":"publisher","first-page":"120151","DOI":"10.1016\/j.biomaterials.2020.120151","volume":"255","author":"KJ Lee","year":"2020","unstructured":"Lee KJ, Ko EJ, Park YY, Park SS, Ju EJ, Park J, et al. A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. Biomaterials. 2020;255:120151.","journal-title":"Biomaterials"},{"key":"7921_CR126","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.molcel.2019.11.004","volume":"77","author":"P Liu","year":"2020","unstructured":"Liu P, Zhao L, Loos F, Marty C, Xie W, Martins I, et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol cell. 2020;77:748\u201360.e9.","journal-title":"Mol cell"},{"key":"7921_CR127","doi-asserted-by":"publisher","first-page":"34375","DOI":"10.18632\/oncotarget.6045","volume":"6","author":"SD Vallabhapurapu","year":"2015","unstructured":"Vallabhapurapu SD, Blanco VM, Sulaiman MK, Vallabhapurapu SL, Chu Z, Franco RS, et al. Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium. Oncotarget. 2015;6:34375\u201388.","journal-title":"Oncotarget"},{"key":"7921_CR128","first-page":"1111","volume":"16","author":"A Elnemr","year":"2000","unstructured":"Elnemr A, Ohta T, Yachie A, Fushida S, Ninomiya I, Nishimura GI, et al. N-ethylmaleimide-enhanced phosphatidylserine externalization of human pancreatic cancer cells and immediate phosphatidylserine-mediated phagocytosis by macrophages. Int J Oncol. 2000;16:1111\u20136.","journal-title":"Int J Oncol"},{"key":"7921_CR129","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1215\/15228517-2-3-174","volume":"2","author":"GH Chang","year":"2000","unstructured":"Chang GH, Barbaro NM, Pieper RO. Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells. Neuro-Oncol. 2000;2:174\u201383.","journal-title":"Neuro-Oncol"},{"key":"7921_CR130","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41577-019-0167-y","volume":"19","author":"G Lemke","year":"2019","unstructured":"Lemke G. How macrophages deal with death. Nat Rev Immunol. 2019;19:539\u201349.","journal-title":"Nat Rev Immunol"},{"key":"7921_CR131","doi-asserted-by":"publisher","first-page":"9214","DOI":"10.7150\/thno.45125","volume":"10","author":"W Chang","year":"2020","unstructured":"Chang W, Fa H, Xiao D, Wang J. Targeting phosphatidylserine for Cancer therapy: prospects and challenges. Theranostics. 2020;10:9214\u201329.","journal-title":"Theranostics"},{"key":"7921_CR132","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/BST20211254","volume":"50","author":"D Vorselen","year":"2022","unstructured":"Vorselen D. Dynamics of phagocytosis mediated by phosphatidylserine. Biochem Soc Trans. 2022;50:1281\u201391.","journal-title":"Biochem Soc Trans"},{"key":"7921_CR133","doi-asserted-by":"publisher","first-page":"856","DOI":"10.18632\/oncotarget.26615","volume":"10","author":"HW Davis","year":"2019","unstructured":"Davis HW, Vallabhapurapu SD, Chu Z, Vallabhapurapu SL, Franco RS, Mierzwa M, et al. Enhanced phosphatidylserine-selective cancer therapy with irradiation and SapC-DOPS nanovesicles. Oncotarget. 2019;10:856\u201368.","journal-title":"Oncotarget"},{"key":"7921_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108620","volume":"34","author":"S Budhu","year":"2021","unstructured":"Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, et al. Targeting Phosphatidylserine enhances the anti-tumor response to tumor-directed radiation therapy in a preclinical model of Melanoma. Cell Rep. 2021;34:108620.","journal-title":"Cell Rep"},{"key":"7921_CR135","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature22076","volume":"544","author":"J Chen","year":"2017","unstructured":"Chen J, Zhong MC, Guo H, Davidson D, Mishel S, Lu Y, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017;544:493\u20137.","journal-title":"Nature"},{"key":"7921_CR136","first-page":"4721","volume":"12","author":"SH Wang","year":"2022","unstructured":"Wang SH, Chou WC, Huang HC, Lee TA, Hsiao TC, Wang LH, et al. Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis. Am J cancer Res. 2022;12:4721\u201336.","journal-title":"Am J cancer Res"},{"key":"7921_CR137","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns P, J\u00f6nsson F. Mouse and human FcR effector functions. Immunol Rev. 2015;268:25\u201351.","journal-title":"Immunol Rev"},{"key":"7921_CR138","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12336","volume":"268","author":"A Getahun","year":"2015","unstructured":"Getahun A, Cambier JC. Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. Immunol Rev. 2015;268:66\u201373.","journal-title":"Immunol Rev"},{"key":"7921_CR139","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s12276-021-00640-9","volume":"53","author":"T Suwa","year":"2021","unstructured":"Suwa T, Kobayashi M, Nam JM, Harada H. Tumor microenvironment and radioresistance. Exp Mol Med. 2021;53:1029\u201335.","journal-title":"Exp Mol Med"},{"key":"7921_CR140","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.4143\/crt.2017.538","volume":"50","author":"H Chang","year":"2018","unstructured":"Chang H, Wei JW, Tao YL, Ding PR, Xia YF, Gao YH, et al. CCR6 is a predicting biomarker of radiosensitivity and potential target of radiosensitization in rectal cancer. Cancer Res Treat. 2018;50:1203\u201313.","journal-title":"Cancer Res Treat"},{"key":"7921_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61958-4","volume":"10","author":"K Li","year":"2020","unstructured":"Li K, Zhu X, Li L, Ning R, Liang Z, Zeng F, et al. Identification of non-invasive biomarkers for predicting the radiosensitivity of nasopharyngeal carcinoma from serum microRNAs. Sci Rep. 2020;10:5161.","journal-title":"Sci Rep"},{"key":"7921_CR142","doi-asserted-by":"publisher","first-page":"20512","DOI":"10.18632\/aging.103907","volume":"12","author":"F Liao","year":"2020","unstructured":"Liao F, Chen X, Peng P, Dong W. RWR-algorithm-based dissection of microRNA-506-3p and microRNA-140-5p as radiosensitive biomarkers in colorectal cancer. Aging. 2020;12:20512\u201322.","journal-title":"Aging"},{"key":"7921_CR143","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403:171\u201382.","journal-title":"Lancet"},{"key":"7921_CR144","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1200\/JCO.24.00081","volume":"42","author":"EB Ludmir","year":"2024","unstructured":"Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, et al. Addition of metastasis-directed therapy to systemic therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A multicenter, randomized Phase II trial. J Clin Oncol. 2024;42:3795\u2013805.","journal-title":"J Clin Oncol"},{"key":"7921_CR145","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of Metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: The EXTEND Phase 2 randomized clinical trial. JAMA Oncol. 2023;9:825\u201334.","journal-title":"JAMA Oncol"},{"key":"7921_CR146","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al. Randomized Phase II Trial of Nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol: J Am Soc Clin Oncol. 2021;39:30\u20137.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"7921_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216727","volume":"588","author":"A Song","year":"2024","unstructured":"Song A, Wu L, Zhang BX, Yang QC, Liu YT, Li H, et al. Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma. Cancer Lett. 2024;588:216727.","journal-title":"Cancer Lett"},{"key":"7921_CR148","doi-asserted-by":"crossref","unstructured":"Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. J Immunother Cancer. 2021;9:e002038.","DOI":"10.1136\/jitc-2020-002038"},{"key":"7921_CR149","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104.","journal-title":"J Hematol Oncol"},{"key":"7921_CR150","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/mc.22879","volume":"57","author":"V Nadella","year":"2018","unstructured":"Nadella V, Singh S, Jain A, Jain M, Vasquez KM, Sharma A, et al. Low dose radiation primed iNOS\u2009+\u2009M1macrophages modulate angiogenic programming of tumor derived endothelium. Mol Carcinogenesis. 2018;57:1664\u201371.","journal-title":"Mol Carcinogenesis"},{"key":"7921_CR151","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer cell. 2013;24:589\u2013602.","journal-title":"Cancer cell"},{"key":"7921_CR152","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1078-0432.CCR-22-2340","volume":"29","author":"AK Cheema","year":"2023","unstructured":"Cheema AK, Li Y, Ventimiglia M, Kowalczyk K, Hankins R, Bandi G, et al. Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers. Clin Cancer Res. 2023;29:921\u20139.","journal-title":"Clin Cancer Res"},{"key":"7921_CR153","doi-asserted-by":"crossref","unstructured":"Lehrer EJ, Prabhu AV, Sindhu KK, Lazarev S, Ruiz-Garcia H, Peterson JL, et al. Proton and heavy particle intracranial radiosurgery. Biomedicines. 2021;9:31.","DOI":"10.3390\/biomedicines9010031"},{"key":"7921_CR154","doi-asserted-by":"crossref","unstructured":"Frijlink E, Bosma DM, Busselaar J, Battaglia TW, Staal MD, Verbrugge I, et al. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice. J Clin Investig. 2024;134:e171154.","DOI":"10.1172\/JCI171154"},{"key":"7921_CR155","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.drudis.2020.11.003","volume":"26","author":"WB Yu","year":"2021","unstructured":"Yu WB, Ye ZH, Chen X, Shi JJ, Lu JJ. The development of small-molecule inhibitors targeting CD47. Drug Discov today. 2021;26:561\u20138.","journal-title":"Drug Discov today"},{"key":"7921_CR156","doi-asserted-by":"publisher","first-page":"e2004853","DOI":"10.1002\/adma.202004853","volume":"32","author":"L Rao","year":"2020","unstructured":"Rao L, Zhao SK, Wen C, Tian R, Lin L, Cai B, et al. Activating macrophage-mediated cancer immunotherapy by genetically edited nanoparticles. Adv Mater. 2020;32:e2004853.","journal-title":"Adv Mater"},{"key":"7921_CR157","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","volume":"25","author":"Y Wang","year":"2019","unstructured":"Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, et al. The reciprocity between radiotherapy and cancer immunotherapy. Clin Cancer Res. 2019;25:1709\u201317.","journal-title":"Clin Cancer Res"},{"key":"7921_CR158","doi-asserted-by":"crossref","unstructured":"Louvel G, Bahleda R, Ammari S, Le P\u00e9choux C, Levy A, Massard C, et al. Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?. Eur Respir J. 2018;51:1701737.","DOI":"10.1183\/13993003.01737-2017"},{"key":"7921_CR159","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-small-cell Lung Cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"7921_CR160","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. J Clin Oncol: J Am Soc Clin Oncol. 2022;40:1301\u201311.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"7921_CR161","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","volume":"17","author":"CM Bestvina","year":"2022","unstructured":"Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, et al. A Phase 1 trial of concurrent or sequential Ipilimumab, Nivolumab, and stereotactic body radiotherapy in patients with Stage IV NSCLC Study. J Thorac Oncol. 2022;17:130\u201340.","journal-title":"J Thorac Oncol"},{"key":"7921_CR162","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250\u20134.","journal-title":"Nature"},{"key":"7921_CR163","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","volume":"35","author":"L Cassetta","year":"2019","unstructured":"Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer cell. 2019;35:588\u2013602.e10.","journal-title":"Cancer cell"},{"key":"7921_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21407-w","volume":"12","author":"N Ochocka","year":"2021","unstructured":"Ochocka N, Segit P, Walentynowicz KA, Wojnicki K, Cyranowski S, Swatler J, et al. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat Commun. 2021;12:1151.","journal-title":"Nat Commun"},{"key":"7921_CR165","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s43018-024-00824-y","volume":"5","author":"X Qiu","year":"2024","unstructured":"Qiu X, Zhou T, Li S, Wu J, Tang J, Ma G, et al. Spatial single-cell protein landscape reveals vimentin(high) macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma. Nat Cancer. 2024;5:1557\u201378.","journal-title":"Nat Cancer"},{"key":"7921_CR166","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","volume":"14","author":"M Matusiak","year":"2024","unstructured":"Matusiak M, Hickey JW, van IDGP, Lu G, Kidzi\u0144ski L, Zhu S, et al. Spatially segregated macrophage populations predict distinct outcomes in colon cancer. Cancer Discov. 2024;14:1418\u201339.","journal-title":"Cancer Discov"},{"key":"7921_CR167","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595:578\u201384.","journal-title":"Nature"},{"key":"7921_CR168","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bbrc.2022.03.158","volume":"608","author":"X Wan","year":"2022","unstructured":"Wan X, Fang M, Chen T, Wang H, Zhou Q, Wei Y, et al. The mechanism of low-dose radiation-induced upregulation of immune checkpoint molecule expression in lung cancer cells. Biochem Biophys Res Commun. 2022;608:102\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"7921_CR169","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s42003-023-04615-6","volume":"6","author":"L Ghantous","year":"2023","unstructured":"Ghantous L, Volman Y, Hefez R, Wald O, Stern E, Friehmann T, et al. The DNA damage response pathway regulates the expression of the immune checkpoint CD47. Commun Biol. 2023;6:245.","journal-title":"Commun Biol"},{"key":"7921_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37328-9","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, et al. STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat Commun. 2023;14:1610.","journal-title":"Nat Commun"},{"key":"7921_CR171","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cimb43010013","volume":"43","author":"H Yoshino","year":"2021","unstructured":"Yoshino H, Sato Y, Nakano M. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1. Curr issues Mol Biol. 2021;43:153\u201362.","journal-title":"Curr issues Mol Biol"},{"key":"7921_CR172","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.718","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, et al. BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. Clin Transl Med. 2022;12:e718.","journal-title":"Clin Transl Med"},{"key":"7921_CR173","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15252\/emmm.201606674","volume":"9","author":"A Azad","year":"2017","unstructured":"Azad A, Yin Lim S, D\u2019Costa Z, Jones K, Diana A, Sansom OJ, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med. 2017;9:167\u201380.","journal-title":"EMBO Mol Med"},{"key":"7921_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0634-9","volume":"7","author":"M Grapin","year":"2019","unstructured":"Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, et al. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer. 2019;7:160.","journal-title":"J Immunother Cancer"},{"key":"7921_CR175","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1158\/1078-0432.CCR-06-0593","volume":"12","author":"EW Newcomb","year":"2006","unstructured":"Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res. 2006;12:4730\u20137.","journal-title":"Clin Cancer Res"},{"key":"7921_CR176","doi-asserted-by":"publisher","first-page":"e26293","DOI":"10.4161\/onci.26293","volume":"2","author":"HL Peters","year":"2013","unstructured":"Peters HL, Yan Y, Solheim JC. APLP2 regulates the expression of MHC class I molecules on irradiated Ewing\u2019s sarcoma cells. Oncoimmunology. 2013;2:e26293.","journal-title":"Oncoimmunology"},{"key":"7921_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64408-3","volume":"10","author":"LK Zebertavage","year":"2020","unstructured":"Zebertavage LK, Alice A, Crittenden MR, Gough MJ. Transcriptional upregulation of NLRC5 by radiation drives STING- and Interferon-independent MHC-I Expression on cancer cells and T Cell Cytotoxicity. Sci Rep. 2020;10:7376.","journal-title":"Sci Rep"},{"key":"7921_CR178","doi-asserted-by":"publisher","first-page":"e32542","DOI":"10.1371\/journal.pone.0032542","volume":"7","author":"S Wan","year":"2012","unstructured":"Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Liu LF. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PloS One. 2012;7:e32542.","journal-title":"PloS One"},{"key":"7921_CR179","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23442-z","volume":"12","author":"Z Bian","year":"2021","unstructured":"Bian Z, Shi L, Kidder K, Zen K, Garnett-Benson C, Liu Y. Intratumoral SIRP\u03b1-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy. Nat Commun. 2021;12:3229.","journal-title":"Nat Commun"},{"key":"7921_CR180","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1753425919876690","volume":"26","author":"S Gholamin","year":"2020","unstructured":"Gholamin S, Youssef OA, Rafat M, Esparza R, Kahn S, Shahin M, et al. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma. Innate Immun. 2020;26:130\u20137.","journal-title":"Innate Immun"},{"key":"7921_CR181","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26:2538\u201345.","journal-title":"Leukemia"},{"key":"7921_CR182","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00262-019-02397-7","volume":"68","author":"AL Schwartz","year":"2019","unstructured":"Schwartz AL, Nath PR, Allgauer M, Lessey-Morillon EC, Sipes JM, Ridnour LA, et al. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunol Immunother. 2019;68:1805\u201317.","journal-title":"Cancer Immunol Immunother"},{"key":"7921_CR183","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0361-7","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018;6:46.","journal-title":"J Immunother Cancer"},{"key":"7921_CR184","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/neuonc\/noz226","volume":"22","author":"CI Ene","year":"2020","unstructured":"Ene CI, Kreuser SA, Jung M, Zhang H, Arora S, White Moyes K, et al. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro-Oncol. 2020;22:639\u201351.","journal-title":"Neuro-Oncol"},{"key":"7921_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123430","volume":"646","author":"X Li","year":"2023","unstructured":"Li X, Chen Y, Wang R, Lu E, Luo K, Sha X. Enhancement of cancer immunotherapy using CRT valgus tumor cell membranes coated bacterial whole peptidoglycan combined with radiotherapy. Int J Pharm. 2023;646:123430.","journal-title":"Int J Pharm"},{"key":"7921_CR186","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s11307-024-01934-w","volume":"26","author":"DF Boreel","year":"2024","unstructured":"Boreel DF, Sandker GGW, Ansems M, van den Bijgaart RJE, Peters JPW, Span PN, et al. MHC-I and PD-L1 Expression is associated with decreased tumor outgrowth and is radiotherapy-inducible in the murine head and neck squamous cell carcinoma model MOC1. Mol Imaging Biol. 2024;26:835\u201346.","journal-title":"Mol Imaging Biol"},{"key":"7921_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"7921_CR188","first-page":"2215","volume":"18","author":"P Soni","year":"2017","unstructured":"Soni P, Qayoom S, Husain N, Kumar P, Chandra A, Ojha BK, et al. CD24 and Nanog expression in Stem Cells in Glioblastoma: Correlation with response to chemoradiation and overall survival. Asian Pac J Cancer Prev. 2017;18:2215\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"7921_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367959","volume":"15","author":"S Huang","year":"2024","unstructured":"Huang S, Zhang X, Wei Y, Xiao Y. Checkpoint CD24 function on tumor and immunotherapy. Front Immunol. 2024;15:1367959.","journal-title":"Front Immunol"},{"key":"7921_CR190","doi-asserted-by":"crossref","unstructured":"Zaib T, Cheng K, Liu T, Mei R, Liu Q, Zhou X, et al. Expression of CD22 in triple-negative breast cancer: a novel prognostic biomarker and potential target for CAR therapy. Int J Mol Sci. 2023;24:2152.","DOI":"10.3390\/ijms24032152"},{"key":"7921_CR191","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.21873\/invivo.13006","volume":"36","author":"MH Kim","year":"2022","unstructured":"Kim MH, Lee JH, Lee JS, Kim DC, Yang JW, An HJ. et al. Fc receptor expression as a prognostic factor in patients with non-small-cell lung cancer. In vivo. 2022;36:2708\u201313.","journal-title":"In vivo"},{"key":"7921_CR192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1174138","volume":"14","author":"P Farhangnia","year":"2023","unstructured":"Farhangnia P, Ghomi SM, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi AA. SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Front Immunol. 2023;14:1174138.","journal-title":"Front Immunol"},{"key":"7921_CR193","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1297473","volume":"15","author":"M Gunes","year":"2024","unstructured":"Gunes M, Rosen ST, Shachar I, Gunes EG. Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors. Front Immunol. 2024;15:1297473.","journal-title":"Front Immunol"},{"key":"7921_CR194","doi-asserted-by":"publisher","first-page":"1249929","DOI":"10.3389\/fphar.2023.1249929","volume":"14","author":"P Machy","year":"2023","unstructured":"Machy P, Mortier E, Birkl\u00e9 S. Biology of GD2 ganglioside: implications for cancer immunotherapy. Front Pharm. 2023;14:1249929.","journal-title":"Front Pharm"},{"key":"7921_CR195","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/jcmm.17669","volume":"27","author":"P Eggleton","year":"2023","unstructured":"Eggleton P, De Alba J, Weinreich M, Calias P, Foulkes R, Corrigall VM. The therapeutic mavericks: Potent immunomodulating chaperones capable of treating human diseases. J Cell Mol Med. 2023;27:322\u201339.","journal-title":"J Cell Mol Med"},{"key":"7921_CR196","doi-asserted-by":"publisher","first-page":"e3000402","DOI":"10.1371\/journal.pbio.3000402","volume":"17","author":"A Han","year":"2019","unstructured":"Han A, Li C, Zahed T, Wong M, Smith I, Hoedel K, et al. Calreticulin is a critical cell survival factor in malignant neoplasms. PLoS Biol. 2019;17:e3000402.","journal-title":"PLoS Biol"},{"key":"7921_CR197","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ccell.2023.04.015","volume":"41","author":"E Guilbaud","year":"2023","unstructured":"Guilbaud E, Kroemer G, Galluzzi L. Calreticulin exposure orchestrates innate immunosurveillance. Cancer cell. 2023;41:1014\u20136.","journal-title":"Cancer cell"},{"key":"7921_CR198","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12964-025-02090-6","volume":"23","author":"R Pulica","year":"2025","unstructured":"Pulica R, Aquib A, Varsanyi C, Gadiyar V, Wang Z, Frederick T, et al. Dys-regulated phosphatidylserine externalization as a cell intrinsic immune escape mechanism in cancer. Cell Commun Signal: CCS. 2025;23:131.","journal-title":"Cell Commun Signal: CCS"},{"key":"7921_CR199","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2017.08.012","volume":"52","author":"B Sharma","year":"2018","unstructured":"Sharma B, Kanwar SS. Phosphatidylserine: A cancer cell targeting biomarker. Semin cancer Biol. 2018;52:17\u201325.","journal-title":"Semin cancer Biol"},{"key":"7921_CR200","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41418-024-01399-y","volume":"32","author":"H Lingel","year":"2025","unstructured":"Lingel H, Fischer L, Remstedt S, Kuropka B, Philipsen L, Han I, et al. SLAMF7 (CD319) on activated CD8(+) T cells transduces environmental cues to initiate cytotoxic effector cell responses. Cell Death Differ. 2025;32:561\u201372.","journal-title":"Cell Death Differ"},{"key":"7921_CR201","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e79","volume":"35","author":"Y Deng","year":"2024","unstructured":"Deng Y, Zhang L, Dai C, Xu Y, Gan Q, Cheng J. SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma. J Gynecol Oncol. 2024;35:e79.","journal-title":"J Gynecol Oncol"},{"key":"7921_CR202","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","volume":"23","author":"HD Skinner","year":"2017","unstructured":"Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, et al. Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res. 2017;23:2713\u201322.","journal-title":"Clin Cancer Res"},{"key":"7921_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16868","volume":"9","author":"S Li","year":"2023","unstructured":"Li S, Xie Y, Zhou W, Zhou Q, Tao D, Yang H, et al. Association of long noncoding RNA MALAT1 with the radiosensitivity of lung adenocarcinoma cells via the miR-140\/PD-L1 axis. Heliyon. 2023;9:e16868.","journal-title":"Heliyon"},{"key":"7921_CR204","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00784-017-2099-x","volume":"22","author":"M Fiedler","year":"2018","unstructured":"Fiedler M, Weber F, Hautmann MG, Haubner F, Reichert TE, Klingelh\u00f6ffer C, et al. Biological predictors of radiosensitivity in head and neck squamous cell carcinoma. Clin Oral Investig. 2018;22:189\u2013200.","journal-title":"Clin Oral Investig"},{"key":"7921_CR205","doi-asserted-by":"publisher","first-page":"937","DOI":"10.7150\/jca.27199","volume":"10","author":"X Lyu","year":"2019","unstructured":"Lyu X, Zhang M, Li G, Jiang Y, Qiao Q. PD-1 and PD-L1 expression predicts radiosensitivity and clinical outcomes in head and neck cancer and is associated with HPV infection. J Cancer. 2019;10:937\u201348.","journal-title":"J Cancer"},{"key":"7921_CR206","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1182\/blood.V81.5.1323.1323","volume":"81","author":"FM Uckun","year":"1993","unstructured":"Uckun FM, Song CW. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood. 1993;81:1323\u201332.","journal-title":"Blood"},{"key":"7921_CR207","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/onc.2012.31","volume":"32","author":"J Bensimon","year":"2013","unstructured":"Bensimon J, Altmeyer-Morel S, Benjelloun H, Chevillard S, Lebeau J. CD24(-\/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability. Oncogene. 2013;32:251\u20138.","journal-title":"Oncogene"},{"key":"7921_CR208","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3892\/ol.2017.6301","volume":"14","author":"L Wang","year":"2017","unstructured":"Wang L, Li P, Hu W, Xia Y, Hu C, Liu L, et al. CD44(+)CD24(+) subset of PANC-1 cells exhibits radiation resistance via decreased levels of reactive oxygen species. Oncol Lett. 2017;14:1341\u20136.","journal-title":"Oncol Lett"},{"key":"7921_CR209","doi-asserted-by":"publisher","first-page":"8662","DOI":"10.1158\/0008-5472.CAN-05-4256","volume":"66","author":"T Okunaga","year":"2006","unstructured":"Okunaga T, Urata Y, Goto S, Matsuo T, Mizota S, Tsutsumi K, et al. Calreticulin, a molecular chaperone in the endoplasmic reticulum, modulates radiosensitivity of human glioblastoma U251MG cells. Cancer Res. 2006;66:8662\u201371.","journal-title":"Cancer Res"},{"key":"7921_CR210","doi-asserted-by":"crossref","unstructured":"Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020;8:e000537.","DOI":"10.1136\/jitc-2020-000537"},{"key":"7921_CR211","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","volume":"108","author":"L Yin","year":"2020","unstructured":"Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int J Radiat Oncol, Biol Phys. 2020;108:212\u201324.","journal-title":"Int J Radiat Oncol, Biol Phys"},{"key":"7921_CR212","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijrobp.2016.02.022","volume":"95","author":"SR Gameiro","year":"2016","unstructured":"Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, et al. Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing. Int J Radiat Oncol, Biol Phys. 2016;95:120\u201330.","journal-title":"Int J Radiat Oncol, Biol Phys"},{"key":"7921_CR213","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2057892","volume":"11","author":"H Zhou","year":"2022","unstructured":"Zhou H, Tu C, Yang P, Li J, Kepp O, Li H, et al. Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice. Oncoimmunology. 2022;11:2057892.","journal-title":"Oncoimmunology"},{"key":"7921_CR214","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.ircmb.2022.11.005","volume":"376","author":"A Bertho","year":"2023","unstructured":"Bertho A, Iturri L, Prezado Y. Radiation-induced immune response in novel radiotherapy approaches FLASH and spatially fractionated radiotherapies. Int Rev Cell Mol Biol. 2023;376:37\u201368.","journal-title":"Int Rev Cell Mol Biol"},{"key":"7921_CR215","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-020-00989-w","volume":"13","author":"TC Kuo","year":"2020","unstructured":"Kuo TC, Chen A, Harrabi O, Sockolosky JT, Zhang A, Sangalang E, et al. Targeting the myeloid checkpoint receptor SIRP\u03b1 potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020;13:160.","journal-title":"J Hematol Oncol"},{"key":"7921_CR216","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","volume":"25","author":"MEW Logtenberg","year":"2019","unstructured":"Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP\u03b1 axis and a target for cancer immunotherapy. Nat Med. 2019;25:612\u20139.","journal-title":"Nat Med"},{"key":"7921_CR217","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3389\/fimmu.2019.03135","volume":"10","author":"A Nigro","year":"2019","unstructured":"Nigro A, Ricciardi L, Salvato I, Sabbatino F, Vitale M, Crescenzi MA, et al. Enhanced expression of CD47 Is associated with off-target resistance to Tyrosine Kinase inhibitor Gefitinib in NSCLC. Front Immunol. 2019;10:3135.","journal-title":"Front Immunol"},{"key":"7921_CR218","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chembiol.2020.06.008","volume":"27","author":"D Hazama","year":"2020","unstructured":"Hazama D, Yin Y, Murata Y, Matsuda M, Okamoto T, Tanaka D, et al. Macrocyclic peptide-mediated blockade of the CD47-SIRP\u03b1 interaction as a potential cancer immunotherapy. Cell Chem Biol. 2020;27:1181\u201391.e7.","journal-title":"Cell Chem Biol"},{"key":"7921_CR219","doi-asserted-by":"publisher","first-page":"e2303835","DOI":"10.1002\/adma.202303835","volume":"35","author":"L Tang","year":"2003","unstructured":"Tang L, Yin Y, Cao Y, Fu C, Liu H, Feng J, et al. Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy. Adv Mater. 2003;35:e2303835.","journal-title":"Adv Mater"},{"key":"7921_CR220","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nnano.2017.69","volume":"12","author":"H Yuan","year":"2017","unstructured":"Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, et al. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat Nanotechnol. 2017;12:763\u20139.","journal-title":"Nat Nanotechnol"},{"key":"7921_CR221","doi-asserted-by":"publisher","first-page":"24071","DOI":"10.1021\/acsami.3c01047","volume":"15","author":"Z Zhan","year":"2023","unstructured":"Zhan Z, Zeng W, Liu J, Zhang L, Cao Y, Li P, et al. Engineered biomimetic copper sulfide nanozyme mediates \u201cDon\u2019t Eat Me\u201d signaling for photothermal and chemodynamic precision therapies of breast cancer. ACS Appl Mater interfaces. 2023;15:24071\u201383.","journal-title":"ACS Appl Mater interfaces"},{"key":"7921_CR222","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41551-018-0203-4","volume":"2","author":"K Lu","year":"2018","unstructured":"Lu K, He C, Guo N, Chan C, Ni K, Lan G, et al. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng. 2018;2:600\u201310.","journal-title":"Nat Biomed Eng"},{"key":"7921_CR223","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201802228","volume":"31","author":"Q Chen","year":"2019","unstructured":"Chen Q, Chen J, Yang Z, Xu J, Xu L, Liang C, et al. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv Mater. 2019;31:e1802228.","journal-title":"Adv Mater"},{"key":"7921_CR224","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373\u20137.","journal-title":"Nature"},{"key":"7921_CR225","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/cncr.30138","volume":"122","author":"JM Qian","year":"2016","unstructured":"Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122:3051\u20138.","journal-title":"Cancer"},{"key":"7921_CR226","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol, Phys. 2015;92:368\u201375.","journal-title":"Int J Radiat Oncol Biol, Phys"},{"key":"7921_CR227","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1007\/s00262-023-03494-4","volume":"72","author":"A Jokim\u00e4ki","year":"2023","unstructured":"Jokim\u00e4ki A, Hietala H, Lemma J, Karhap\u00e4\u00e4 H, Rintala A, Kaikkonen JP, et al. Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events. Cancer Immunol Immunother. 2023;72:3337\u201347.","journal-title":"Cancer Immunol Immunother"},{"key":"7921_CR228","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijrobp.2020.01.043","volume":"108","author":"DA Pomeranz Krummel","year":"2020","unstructured":"Pomeranz Krummel DA, Nasti TH, Izar B, Press RH, Xu M, Lowder L, et al. Impact of sequencing radiation therapy and immune checkpoint inhibitors in the treatment of melanoma brain metastases. Int J Radiat Oncol, Biol, Phys. 2020;108:157\u201363.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"7921_CR229","doi-asserted-by":"crossref","unstructured":"Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Ebstein S, Cortez C, et al. Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol. 2021;6:eabg0117.","DOI":"10.1126\/sciimmunol.abg0117"},{"key":"7921_CR230","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","volume":"96","author":"R Qin","year":"2016","unstructured":"Qin R, Olson A, Singh B, Thomas S, Wolf S, Bhavsar NA, et al. Safety and efficacy of radiation therapy in advanced melanoma patients treated with Ipilimumab. Int J Radiat Oncol, Biol, Phys. 2016;96:72\u20137.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"7921_CR231","doi-asserted-by":"publisher","first-page":"9581","DOI":"10.1002\/cam4.3561","volume":"9","author":"L Han","year":"2020","unstructured":"Han L, Shi H, Luo Y, Sun W, Li S, Zhang N, et al. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma. Cancer Med. 2020;9:9581\u201394.","journal-title":"Cancer Med"},{"key":"7921_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-021-00200-0","volume":"6","author":"YH Dai","year":"2021","unstructured":"Dai YH, Wang YF, Shen PC, Lo CH, Yang JF, Lin CS, et al. Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy. NPJ Genom Med. 2021;6:40.","journal-title":"NPJ Genom Med"},{"key":"7921_CR233","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.23.00627","volume":"42","author":"N Ohri","year":"2024","unstructured":"Ohri N, Jolly S, Cooper BT, Kabarriti R, Bodner WR, Klein J, et al. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT). J Clin Oncol: J Am Soc Clin Oncol. 2024;42:562\u201370.","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"7921_CR234","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s43018-023-00547-6","volume":"4","author":"L van Hooren","year":"2023","unstructured":"van Hooren L, Handgraaf SM, Kloosterman DJ, Karimi E, van Mil L, Gassama AA, et al. CD103(+) regulatory T cells underlie resistance to radio-immunotherapy and impair CD8(+) T cell activation in glioblastoma. Nat Cancer. 2023;4:665\u201381.","journal-title":"Nat Cancer"},{"key":"7921_CR235","doi-asserted-by":"crossref","unstructured":"Zafra J, Onieva JL, Oliver J, Garrido-Barros M, Gonz\u00e1lez-Hern\u00e1ndez A, Mart\u00ednez-G\u00e1lvez B, et al. Novel blood biomarkers for response prediction and monitoring of stereotactic ablative radiotherapy and immunotherapy in metastatic oligoprogressive lung cancer. Int J Mol Scii. 2024;25:4533.","DOI":"10.3390\/ijms25084533"},{"key":"7921_CR236","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.radonc.2022.06.016","volume":"173","author":"G Ratnayake","year":"2022","unstructured":"Ratnayake G, Reinwald S, Edwards J, Wong N, Yu D, Ward R, et al. Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy. Radiother Oncol: J Eur Soc Ther Radio Oncol. 2022;173:299\u2013305.","journal-title":"Radiother Oncol: J Eur Soc Ther Radio Oncol"},{"key":"7921_CR237","doi-asserted-by":"crossref","unstructured":"Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, et al. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. J Immunother Cancer. 2020;8:e001429.","DOI":"10.1136\/jitc-2020-001429"},{"key":"7921_CR238","doi-asserted-by":"publisher","first-page":"109728","DOI":"10.1016\/j.radonc.2023.109728","volume":"185","author":"B Grambozov","year":"2023","unstructured":"Grambozov B, Kalantari F, Beheshti M, Stana M, Karner J, Ruznic E, et al. Pretreatment 18-FDG-PET\/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy. Radiother Oncol: J Eur Soc Ther Radio Oncol. 2023;185:109728.","journal-title":"Radiother Oncol: J Eur Soc Ther Radio Oncol"},{"key":"7921_CR239","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1350914","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Gong G, Sun Q, Meng X. Prediction of pCR based on clinical-radiomic model in patients with locally advanced ESCC treated with neoadjuvant immunotherapy plus chemoradiotherapy. Front Oncol. 2024;14:1350914.","journal-title":"Front Oncol"},{"key":"7921_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58684-6","volume":"14","author":"H Peng","year":"2024","unstructured":"Peng H, Moore C, Zhang Y, Saha D, Jiang S, Timmerman R. An AI-based approach for modeling the synergy between radiotherapy and immunotherapy. Sci Rep. 2024;14:8250.","journal-title":"Sci Rep"},{"key":"7921_CR241","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick DT, Le PM, et al. Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature. 2021;596:119\u201325.","journal-title":"Nature"},{"key":"7921_CR242","doi-asserted-by":"publisher","first-page":"eabd5778.","DOI":"10.1126\/sciimmunol.abd5778","volume":"6","author":"P Gueguen","year":"2021","unstructured":"Gueguen P, Metoikidou C, Dupic T, Lawand M, Goudot C, Baulande S, et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8(+) T cell populations in lung cancer. Sci Immunol. 2021;6:eabd5778.","journal-title":"Sci Immunol"},{"key":"7921_CR243","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564:268\u201372.","journal-title":"Nature"},{"key":"7921_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35238-w","volume":"14","author":"S Tietscher","year":"2023","unstructured":"Tietscher S, Wagner J, Anzeneder T, Langwieder C, Rees M, Sobottka B, et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun. 2023;14:98.","journal-title":"Nat Commun"},{"key":"7921_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00774-9","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Zota V, Vincent MY, Clossey D, Chen JJ, Cieslewicz M, et al. Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment. NPJ Precis Oncol. 2024;8:278.","journal-title":"NPJ Precis Oncol"},{"key":"7921_CR246","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10238-025-01641-y","volume":"25","author":"M Soltani","year":"2025","unstructured":"Soltani M, Abbaszadeh M, Fouladseresht H, Sullman MJM, Eskandari N. PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities. Clin Exp Med. 2025;25:106.","journal-title":"Clin Exp Med"},{"key":"7921_CR247","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CJI.0000000000000553","volume":"48","author":"X Cao","year":"2025","unstructured":"Cao X, Ren X, Song Y, Sun Q, Mao F, Shen S, et al. High Expression of Calreticulin affected the tumor microenvironment and correlated with worse prognosis in patients with triple-negative breast cancer. J Immunother. 2025;48:173\u201382.","journal-title":"J Immunother"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07921-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:43:04Z","timestamp":1757410984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":247,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7921"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07921-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"630"}}